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Summary
Background.— European guidelines recommend that antihypertensive management should beBlood pressure; graded as a function of total cardiovascular risk.
Valsartan;
Angiotensin II type 1;
Receptor blockers
Aims.— To examine the multilevel (patient- and physician-level) determinants of blood pressure
and residual total cardiovascular risk outcomes associated with second-line valsartan therapy.
Methods.— The BSCORE study was a prospective, multi-centre, pharmacoepidemiological study
of the ‘‘real-world’’ effectiveness of second-line valsartan with or without hydrochlorothiazide.
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; ESC, European Society of Cardiology; ESH, European Society of Hyper-
ension; GP, general practitioner; ICC, intraclass correlation coefﬁcient; OR, odds ratio; SBP, systolic blood pressure; SCORE, Systematic
Oronary Risk Evaluation; SD, standard deviation; TCVR, total cardiovascular risk.
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Treatment
effectiveness
Results A total of 3497 patients were recruited by 354 physicians. Mean age was 63.8± 12.0
years; 52.3% were male; 20.9% were smokers; 47.7% were dyslipidaemic; and 23.6% had dia-
betes. On average, reductions in blood pressure and increases in the proportions of patients with
controlled blood pressure after 90 days were statistically signiﬁcant (all P < 0.001). Twenty-one
percent of systolic blood pressure and 25.6% of diastolic blood pressure variability at follow-up
was attributable to physician-level characteristics. Signiﬁcant reductions in total cardiovas-
cular risk were observed (P < 0.001); with 12.5% of the variability in total cardiovascular risk
change attributable to physician-level characteristics. Several independent determinants of
blood pressure outcomes were identiﬁed, many of which are modiﬁable.
Conclusions.— Second-line valsartan therapy improves blood pressure outcomes under vari-
able real-world conditions, and is associated with a decrease in total cardiovascular risk.
Optimizing antihypertensive effectiveness, including the reduction of residual cardiovascular
risk, involves managing concomitant conditions and risk factors, improving adherence, and
identifying physician-level factors amenable to intervention.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation.— Les recommandations européennes indiquent que la prise en charge de
l’hypertension artérielle doit être basée sur l’évaluation du risque cardiovasculaire global.
Objectifs.— Examiner les déterminants à deux niveaux (patients et médecins) de la pression
artérielle ainsi que le risque cardiovasculaire global, associés à un traitement par valsartan de
deuxième ligne.
Méthodes.— L’étude BSCORE est une étude prospective, multicentrique, pharmaco-
épidémiologique d’évaluation de l’efﬁcacité dans le monde réel d’un traitement par valsartan
de seconde ligne, avec ou sans hydrochrlorothiazide.
Résultats.— Trois mille quatre cent quatre-vingt-dix-sept patients ont été recrutés par
354médecins. L’âge moyen était de 63,8± 12 ans ; 52,3 % des patients étaient des hommes,
20,9 % des fumeurs ; 40,7 % présentaient une dyslipidémie et 23,6 % un diabète. En moyenne,
la réduction de la pression artérielle et l’augmentation de la proportion de patients ayant une
pression artérielle contrôlée dans les 90 jours étaient statistiquement signiﬁcatives (P < 0,001).
Vingt-et-un pour cent des chiffres de pression artérielle systolique et 25,6 % de la variabilité des
chiffres de pression artérielle diastolique lors du suivi étaient attribuables à l’intervention médi-
cale. Une réduction signiﬁcative du risque cardiovasculaire global a été observée (P < 0,001) ;
avec une variabilité de 12,5 % du risque cardiovasculaire global lié aux caractéristiques de
l’intervention médicale. Plusieurs déterminants indépendants de l’évolution de la pression
artérielle ont été identiﬁés dont plusieurs sont des facteurs de risque modiﬁables.
Conclusions.— Un traitement par valsartan de deuxième ligne améliore le contrôle de la pres-
sion artérielle, dans les conditions d’évaluation du monde réel, et est associé à une diminution
du risque cardiovasculaire global. Optimiser l’efﬁcacité du traitement hypotenseur en inclu-
ant la réduction du risque cardiovasculaire global, implique la prise en charge des pathologies
associées concomitantes et des facteurs de risque, contribue à l’amélioration de l’observance,
et permet d’identiﬁer des facteurs modiﬁables par une intervention thérapeutique liée au
médecin.
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Introduction
Approximately 50% of cardiovascular disease can be
attributed to suboptimal BP control [1]. The ESH-ESC Guide-
lines [2] and the 2009 ESH guideline reappraisal [3] advocate
quantifying patients’ TCVR based on BP values and other risk
factors or associated organ damage, and grading the inten-
sity of antihypertensive management as a function of TCVR.
The SCORE project developed 10-year risk models of fatal
cardiovascular disease for various European countries [4].
The Belgian model (B-SCORE), which incorporated gender,
age, smoking status, systolic BP, and total cholesterol level,
was calibrated based on national mortality statistics and
p
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revalence estimates of major cardiovascular risk factors
5]. The ESH-ESC has recommended that TCVR classiﬁcation
hould be part of clinical assessment and treatment plan-
ing, but it has not been used as an effectiveness outcome.
We recently applied a novel analytical framework
or observational ‘‘real world’’ effectiveness studies to
xamine the determinants and outcomes of second-line
ntihypertensive treatment with valsartan (the PREVIEW
tudy) [6—9]. This framework assumes that patients seen
y the same physician share a commonality deﬁned by that
hysician’s knowledge, experience, and expertise (physician
lass effect). As such, statistical independence of patients
‘nested’’ under physicians cannot be assumed, and hierar-
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hical (or multilevel) analytical approaches are warranted
10]. From a sample of 3194 Belgian patients cared for by
04 GPs, we found that about a quarter of the variability in
P values at 90 days was attributable to the compliance of
hese GPs with the ESH-ESC recommended triggers for treat-
ent initiation and intensiﬁcation, their practice patterns,
xperience in treating hypertension, and years in practice
6]. The remainder of the variance in BP was accounted for
y patient-level variables, many of which were modiﬁable
nd manageable by evidence-based medical care and effec-
ive patient self-care. Similar factors were identiﬁed in an
nalysis of why certain patients did not achieve BP control.
PREVIEW was the ﬁrst observational study of its kind
n hypertension, and we believe it is in need of replica-
ion. The B-SCORE risk classiﬁcation model enabled us to
ot only replicate the PREVIEW study, but also to assess
hysician- and patient-level variables inﬂuencing changes
n TCVR and to identify determining factors reducing TCVR
fter second-line treatment with valsartan with or without
ydrochlorothiazide (hereafter referred to as valsartan).
ethods
he observational BSCORE study (so named to emphasize
ts link to the B-SCORE risk model) was designed as a
rospective, open-label, multicentre, multilevel (patients
ested under physicians) pharmacoepidemiological study of
redictors of, and changes in, BP and TCVR in patients
ith hypertension after 90 days of treatment with valsar-
an. Being partly a replication of PREVIEW, the methodology
as virtually identical to the PREVIEW study [6], except
or the addition of TCVR calculation according to the B-
CORE model. Only key elements of the methodology are
ummarized below. Further details are available from the
orresponding author on: recruitment, screening and enrol-
ent procedures; sample size calculations; schedule of
ssessment; complete data model; details on variables and
easurement; procedures for data collection and manage-
ent; and statistical analysis methods.
To be eligible, patients had to be consenting adults
male or female) who did not tolerate and/or who
id not beneﬁt sufﬁciently from prior antihypertensive
reatment, as evidenced by systolic BP (SBP)≥ 140mmHg
nd/or diastolic BP (DBP)≥ 90mmHg (except for patients
ith diabetes, in which case investigators were asked
o consider the 2007 ESH-ESC recommended levels of
BP≥ 130mmHg and DBP≥ 80mmHg); and who were started
e novo on one of the following commercially avail-
ble valsartan formulations: 80mg, 160mg, 80mg/12.5mg
ydrochlorothiazide, 160mg/12.5mg hydrochlorothiazide,
r 160mg/25mg hydrochlorothiazide. Patients could be on
ither valsartan mono- or combination therapy. Patients who
id not tolerate prior antihypertensive treatment were eli-
ible, hence the presence of 2% of patients with baseline
ormal and high normal BP in the sample. The evaluable
ample, deﬁned primarily as patients with baseline and
ollow-up BP values, included 3497 patients contributed by
54 from all over Belgium.
Patient baseline data included: demographics; anthro-
ometrics; hypertension and cardiovascular history; comor-
idities; lifestyle; prior antihypertensive medications; BP;
d
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CVR; clinical status; starting valsartan dose; concomi-
ant antihypertensive and other relevant medications; and
dherence. Data recorded at 90-day follow-up were: BP;
esidual TCVR; clinical status; changes in valsartan dose
ince previous visit; concomitant medication(s) taken or
hanged since previous visit; self-reported adherence within
he past 4 weeks; and side-effects over the past 90 days.
nly patient data collected routinely in clinical practice
ere recorded; no additional tests or exams were ordered.
Separately, and using a specially developed ques-
ionnaire, we also assessed several physician variables
hat might inﬂuence BP or TCVR outcomes: practice
ype, location/setting, patient mix; demographics; sources
f information and knowledge related to hypertension;
ypertension management practices; prescription patterns;
anagement of adverse effects; SBP/DBP thresholds for
reatment initiation and intensiﬁcation; perceptions of
atient adherence; and knowledge of practice guidelines.
BP was measured three times at 1—2-minute intervals,
n a sitting position after 5minutes of rest. The mean
as recorded as the mean sitting SBP and mean DBP. BP
ontrol was deﬁned as per the 2007 ESH-ESC guidelines
s SBP < 140mmHg and DBP < 90mmHg; except for patients
ith diabetes mellitus and/or high or very high TCVR, in
hich case targets were SBP < 130mmHg and DBP < 80mmHg
2]. Of note, the 2009 update [3] advocates a 140/90mmHg
ut-off for all populations, but our study was conducted
nder the 2007 guidelines [2].
TCVR was computed based on the cross-classiﬁcation
f BP by risk factors (e.g. smoking and dyslipidaemia),
etabolic syndrome, organ damage, diabetes, and estab-
ished cardiovascular or renal disease (myocardial infarc-
ion, coronary blood vessel disease, heart failure, cere-
rovascular conditions, peripheral vascular conditions, and
enal conditions [deﬁned as serum creatinine > 1.5mg/dL])
2]. Possible classiﬁcations included: average risk, low added
isk, moderate added risk, high-added risk, and very high-
dded risk. We computed ‘‘change in TCVR’’ by subtracting
CVR at baseline from TCVR at the end of treatment, yield-
ng possible scores from −4 (greatest TCVR improvement
ossible; from very high added to average risk) to + 4 (great-
st TCVR worsening; from average to very high added risk).
atients with established cardiovascular or renal disease
ere not included in the TCVR calculations and analyses as
hey cannot improve according to the ESH-ESC TCVR classi-
cation. We also classiﬁed patients dichotomously as having
chieved, or not, a reduction of at least one level of TCVR at
0 days (excluding patients who were in the average risk cat-
gory at baseline and those with established cardiovascular
r renal disease).
The ESH-ESC guidelines [2], recommend different BP
hresholds for the general population and for patients with
iabetes and/or high/very high risk. Hence, using baseline
ata, we classiﬁed patients in a binary manner as average
o moderate added risk (LOW risk) or diabetes and/or high
dded/very high-added risk (HIGH risk). This classiﬁcation
as used in the evaluation of BP values and BP control over
he 90-day study period.Descriptive statistics of frequency, central tendency, and
ispersion were applied under consideration of levels of
easurement. The t-test for dependent samples was used
o measure BP changes over time; the McNemar test was
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Table 1 Effectiveness outcomes at baseline and after 90 days of treatment.
Mean± SD BP (mmHg) Patients meeting recommended target
Baseline 90 days  Baseline (%) 90 days (%)  by factor of
SBP
All patients (n = 3497) 154.7 ± 15.3 135.3 ± 11.5 −19.5 ± 16.2 4.6 36.9 8.0
LOW risk (n = 1359) 152.1 ± 11.4 135.0 ± 10.4 −17.2 ± 13.1 8.0 60.2 7.5
HIGH risk (n = 2116) 156.4 ± 17.1 135.5 ± 12.2 −20.9 ± 17.8 2.4 22.0 9.2
DBP
All patients (n = 3497) 90.7 ± 9.8 80.7 ± 7.7 −10.0 ± 10.4 16.5 48.8 3.0
LOW risk (n = 1359) 89.9 ± 8.6 80.8 ± 7.5 −9.1 ± 9.4 33.1 83.7 2.5
HIGH risk (n = 2116) 91.2 ± 10.5 80.7 ± 7.9 −10.5 ± 11.0 5.9 26.4 4.5
Combined SBP/DBP
All patients (n = 3497) 3.0 28.7 9.6
LOW risk (n = 1359) 6.2 56.2 9.1
HIGH risk (n = 2116) 0.9 11.1 12.3
TCVR Mean± SD change in TCVR score Reduction in TCVR (%)
All patients (n = 2344) −0.75 ± 0.94 60.9
LOW risk (n = 1370) −0.68 ± 0.85 62.5
HIGH risk (n = 974) −0.85 ± 1.05 58.5
BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure; SD: standard deviation; TCVR: total cardiovascular
risk. Note that the 2007 ESH-ESC-recommended BP targets differ for the general population (those with no or low cardiovascular risk
[LOW risk]) than for those with diabetes and/or high/very high cardiovascular risk (HIGH risk) [2]. The targets are SBP < 140mmHg and
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targets was derived from a total of 3475 patients as 22 patients c
used for changes in proportions in BP control and TCVR
reduction of at least one level. We used conditional hierar-
chical/multilevel linear modelling to identify patient- and
physician-level determinants of changes in BP and TCVR;
unconditional hierarchical/multilevel linear modelling to
calculate the proportion of variability in these variables
attributable to physicians (ICC); and logistic regression mod-
elling to identify independent predictors of uncontrolled BP
and improvement in TCVR.
Results
Patients
Among 3497 patients, the mean age was 63.8± 12.0 years
(range 19—98 years); 13.0% were < 50 years old, 52.4% were
aged 50—69 years, and 34.6% were≥ 70 years old. Around
half were male (52.3%), 20.9% were smokers, 23.6% had
diabetes, and 47.7% were dyslipidaemic. With regard to
cardiovascular conditions, 11.0% had coronary blood ves-
sel disease, 8.9% peripheral vascular conditions, 8.3% had
a history of myocardial infarction, 7.6% had cerebrovascular
conditions, and 5.5% had heart failure. Only 3.6% had renal
disease, and 19.7% had no pre-existing conditions.
For the 3475 patients (99.4%) for whom binary risk status
at baseline could be calculated, 1359 patients (39.1%) were
in the LOW-risk and 2116 patients (60.9%) were in the HIGH-
risk category at baseline. TCVR could be calculated for 2344
patients (67.0%) who had data available at both baseline
and follow-up. Note that 2% of patients had normal or high
M
H
Sn HIGH-risk patients. The % of patients meeting recommended
not be classiﬁed due to missing data related to risk factors.
ormal BP at baseline. These were patients who, despite
herapeutic beneﬁts, did not tolerate prior BP-lowering
reatment and were converted to a valsartan regimen.
ffectiveness outcomes
lood pressure
eductions in mean SBP and DBP, and increases in the
roportions of patients with controlled BP after 90 days
n valsartan (Table 1), were statistically signiﬁcant in the
ntire sample and in the LOW-risk and HIGH-risk groups
all P < 0.0001). At baseline, the HIGH-risk group had signiﬁ-
antly higher mean SBP and DBP levels than the LOW-risk
roup (both P < 0.001) However, this was not the case at
ollow-up, indicating a proportionately higher reduction in
P among HIGH-risk patients.
otal cardiovascular risk
f the 2344 patients for whom TCVR could be calculated,
0.9% showed a reduction in TCVR classiﬁcation by at least
ne category after 90 days of valsartan treatment (Table 1).
ean TCVR reduction was signiﬁcantly higher among HIGH-
isk than LOW-risk patients (P < 0.001). The difference in
roportions of patients achieving versus not achieving a
eduction in TCVR was not statistically signiﬁcant between
IGH- and LOW-risk patients.odelling of blood pressure outcomes
ierarchical/multilevel modelling revealed that 21.0% of
BP and 25.6% of DBP variability at follow-up was
432 R. Lins et al.
Figure 1. Distribution of TCVR (A) at baseline and (B) after 90 days of treatment with valsartan, for those patients for whom TCVR could
be calculated at both time points; and the shifts in proportions from baseline to follow-up (C; dependent samples t-test signiﬁcant with
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p< 0.0001). BP: blood pressure; CV: cardiovascular; DM: diabetes m
otal cardiovascular risk.
ttributable to physician-level characteristics (ICCs = 0.210
nd 0.256, respectively). SBP increased from an intercept of
12.0mmHg as a function of SBP at diagnosis of hypertension
+0.0621mmHg per prior mmHg; P < 0.001) and at baseline
+0.1859mmHg per prior mmHg; P < 0.001), and of concur-
ent treatment with a calcium antagonist (+0.8568mmHg;
= 0.049); but decreased based on physician-rated patient
dherence (−0.1859mmHg for each point on a scale of
—100; P < 0.001). DBP increased from an intercept of
1.8mmHg as a function of DBP at diagnosis of hyper-
ension (+0.0333mmHg per prior mmHg; P < 0.011) and at
aseline (+0.1817mmHg per prior mmHg; P < 0.001), and
hether physicians could identify the appropriate initial
ntihypertensive treatment for patients without known risk
actors (+1.3153mmHg; P < 0.001). DBP decreased based on
hysician-rated patient adherence (−0.0899mmHg for each
oint on a scale of 0—100; P < 0.001), patients’ self-report
f being adherent (−0.6802mmHg; P = 0.030), and patient
ge (−0.0422mmHg per year of age; P < 0.001).
Logistic regression modelling showed that the sole
redictor of uncontrolled SBP at follow-up was a TCVR clas-
iﬁcation of high-added risk ([OR] 8.55, 95% conﬁdence
r
t
fs; MS: metabolic syndrome; OD: subclinical organ damage; TCVR:
nterval [CI] 2.01—36.40; P = 0.004). Predictors of uncon-
rolled DBP included TCVR status of very high (OR = 39.44,
5% CI 5.19—299.95; P < 0.001), high (OR = 43.75, 95%
I 5.78—331.30; P < 0.001), and moderate added risk
OR = 8.25, 95% CI 1.07—63.62; P = 0.043) status. Predictors
f both uncontrolled SBP and DBP were very high (OR = 27.17
95% CI 3.47—212.96]; P = 0.002), high (OR = 7.50, 95% CI
.60—21.58; P < 0.001), and moderate added risk (OR = 2.22,
5% CI 1.05—4.68; P = 0.037).
odelling of TCVR
hange in total cardiovascular risk
sing the colour coding of the ESH-ESC classiﬁcation [2],
ig. 1 shows the cross-classiﬁcation of cardiovascular risk
actors and BP at baseline (Fig. 1A) and follow-up (Fig. 1B)
n = 2575), as well as the statistically signiﬁcant shift in pro-
ortions (Fig. 1C; P < 0.001). The change in TCVR scores
anged from—4 to + 3 among the 2344 patients included in
he computation (mean± SD =−0.75± 0.94).
The proportion of variability in change in TCVR accounted
or by the class effect of physicians was 12.5% (ICC = 0.125).
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From an intercept of 0.982, residual TCVR decreased as a
function of physician-rated patient adherence (−0.009 per
point on a scale of 0—100; P < 0.001), of the absence of pre-
existing cardiovascular risk factors (−0.395; P < 0.001), and
of a very high (−3.263; P < 0.001), high (−2.215; P < 0.001),
moderate (−1.644; p <0.001), or low added risk (−0.932;
P < 0.001) status at baseline. However, residual TCVR was
increased by patients’ SBP at the time of diagnosis of hyper-
tension (+0.0037 per prior mmHg; P = 0.001), by the presence
of diabetes (+0.750; P < 0.001) or dyslipidaemia (+0.1925;
P < 0.001), and whether physicians knew the appropriate ini-
tial antihypertensive treatment for patients with one or two
known risk factors (+0.148; P = 0.027).
Reduction in total cardiovascular risk
Predictors of improvement in patients’ TCVR by at least
one level included: physician-rated patient adherence
(OR = 1.03 per point on a scale of 0—100, 95% CI 1.02—1.05;
P < 0.001); no pre-existing cardiovascular risk conditions
(OR = 2.07, 95% CI 1.38—3.11; P < 0.001); baseline status of
very high (OR = 104.28, 95%, CI: 31.24—349.17; P < 0.001),
high (OR = 11.12, 95% CI 2.31—12.95; P < 0.001), or moder-
ate added risk (OR = 5.57, 95% CI 2.31—12.95; P < 0.001); and
being treated concomitantly with another antihypertensive
agent (OR = 2.28. 95% CI 1.11—4.68; P = 0.025), apart from
alpha-blockers (OR = 0.51, 95% CI 0.26—0.99; P = 0.046).
Improvement in TCVR was also impaired by being diabetic
(OR = 0.19, 95% CI 0.14—0.27; P < 0.001) or dyslipidaemic
(OR = 0.71, 95% CI 0.54—0.96; P = 0.024), and having both SBP
and DBP controlled at baseline (OR = 0.50, 95% CI 0.28—0.92;
P = 0.025).
Discussion
Perhaps most signiﬁcant is our ﬁnding that 90-day second-
line treatment with valsartan produces signiﬁcant downward
shifts in residual TCVR, in addition to improving BP out-
comes. To the best of our knowledge, the BSCORE study is
among the ﬁrst to use the ESH-ESC TCVR classiﬁcation as
an outcome of antihypertensive therapy, rather than just
a determinant. This study further conﬁrms that valsartan
is a highly effective antihypertensive agent for patients in
whom prior treatment failed or was not tolerated [11], yet
adds that this antihypertensive effect is achieved both in
patients with average to moderate risk (LOW risk) and in
those with diabetes and/or high/very high cardiovascular
risk (HIGH risk) according to the ESC-ESH risk classiﬁcation
[2,3].
For instance, at baseline 45.0% of patients were in the
high and very high-added risk categories, and after 90 days
of valsartan treatment, this was reduced to 24.7%. Simi-
larly, the proportion of patients in the moderate added risk
group decreased from 41.6% at baseline to 26.4% at follow-
up. Conversely, 90 days of valsartan treatment increased
the group of patients with average or low added risk by a
factor of 3.7 from 13.4% (2.0 and 11.4%, respectively) at
baseline to 49.6% (14.0 and 35.6%, respectively). This con-
ﬁrms that when the room for improvement in TCVR is larger,
such improvement is indeed likely to occur in many patients.
In fact, the worse the TCVR score at baseline, the greater the
odds for improvement. Conversely, patients with controlled
a
a
p
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BP and DBP at baseline (less room for improvement) were
ess likely to show improvement in TCVR, as these patients
ere started on valsartan because ﬁrst-line treatment was
ot tolerated.
The physician class-effect was less pronounced in the
hange in TCVR (12.5%) compared to changes in SBP (21.0%)
nd DBP (25.6%). This could mean that details of the TCVR
lassiﬁcation may be easier for clinicians to remember than
he BP thresholds for treatment initiation or intensiﬁcation.
his validates the use of the TCVR classiﬁcation as a support
ool in the clinical management of hypertension.
The ﬁnding that physicians’ knowledge of the appro-
riate antihypertensive treatment for patients with none,
ne, or two risk factors had a negative impact on out-
omes may seem paradoxical. However, it may indicate that
imited knowledge about high-risk patients impaired physi-
ians’ ability to treat more complex patients at second
nd, arguably, later lines of antihypertensive therapy. Also
eemingly paradoxical, the weak (P = 0.049) SBP-elevating
+0.86mmHg) effect of concomitant treatment with a cal-
ium antagonist may be a proxy reference to a subgroup of
atients who have comorbidities where such treatment is
ndicated (peripheral artery disease, angina, and metabolic
yndrome).
The multilevel models were less detailed in terms of
hysician- and patient-level determinants than those in the
REVIEW study and some of its subgroup analyses that have
een published [6—8] or are in progress (stratiﬁcations by
ardiovascular risk, body mass index, hyperlipidaemia, dia-
etes, gender, and smoking). However, the proportions of
ariability in BP outcomes attributed to the class effect
f physicians in BSCORE (21.0 and 25.6%) were compara-
le to those in PREVIEW [6]. Thus, future research should
ocus on identifying physician-level factors that are helpful
n explaining variance in the effectiveness of antihyper-
ensive treatment. To this end, several studies similar to
REVIEW and BSCORE are underway for a ﬁxed-dose combi-
ation of valsartan and amlodipine, and for the new direct
enin inhibitor, aliskiren, and its ﬁxed-dose combination with
ydrochlorothiazide.
An innovation in the BSCORE study is the use of the TCVR
lassiﬁcation as an outcome variable in the assessment of
he effectiveness of valsartan as second-line antihyperten-
ive treatment. Given that BP control may continue to be a
oving target, TCVR outcome data can provide critical infor-
ation from which to estimate treatment effectiveness. As
ntihypertensive treatment needs to be based on both BP
alues and TCVR assessment, the BSCORE study provides pre-
iminary evidence of the clinical relevance of incorporating
CVR as an index of treatment outcomes—even though the
nly factor impacted on in this study is BP, and the observed
mprovements in TCVR are attributable only to treatment.
Improvement in TCVR was a function of patient adher-
nce and TCVR at baseline—with signiﬁcant downward
hifts among both LOW- and HIGH-risk patients. Dyslipi-
aemia and diabetes may inhibit this risk reduction effect
f valsartan; however, dyslipidaemia is a modiﬁable factor
nd diabetes is a manageable factor. A treatment plan for
patient with hypertension should target the elevated BP,
s well as dyslipidaemia and diabetes in order to optimize
atient outcomes. Future studies are needed to evalu-
te how the comprehensive management of the various
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Ann Intern Med 2010. Available at: http://www.annals.org/
content/152/11/689.full/reply#annintmed el 12482934
lements of TCVR (e.g. lipids, glucose, and lifestyle risk
actors), not just hypertension, translate into lower resid-
al cardiovascular risk [12]— and ensuring that sufﬁcient
atients are enrolled, with the required data, to minimize
he loss of subjects in analyses.
onclusions
inety days of second-line antihypertensive therapy with
alsartan reduced BP values and improved BP control under
ariable real-world conditions. Treatment was also asso-
iated with decreases in patients’ TCVR status— including
atients at advanced risk levels. ESH-ESC guidelines rec-
mmend that TCVR be used in the assessment of need for
ntihypertensive therapy. Yet our study also validates the
se of the ESH-ESC classiﬁcation of TCVR as an outcome
ariable when evaluating the efﬁcacy and effectiveness of
ntihypertensive therapy.
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